Alliancebernstein L.P. Aeglea Bio Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.5 - $2.66 $10,800 - $57,456	-21,600 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.87 - $4.77 $7,480 - $19,080	-4,000 Reduced 15.63%	21,600 $50,000
Q2 2021 Jul 30, 2021	BUY	$6.32 - $8.38 $13,904 - $18,436	2,200 Added 9.4%	25,600 $178,000
Q1 2021 May 06, 2021	SELL	$6.76 - $8.57 $3,380 - $4,285	-500 Reduced 2.09%	23,400 $185,000
Q4 2020 Feb 08, 2021	SELL	$7.02 - $9.83 $20,358 - $28,507	-2,900 Reduced 10.82%	23,900 $188,000
Q3 2020 Nov 12, 2020	BUY	$6.51 - $9.33 $13,020 - $18,660	2,000 Added 8.06%	26,800 $190,000
Q2 2020 Aug 13, 2020	BUY	$4.01 - $11.04 $59,348 - $163,392	14,800 Added 148.0%	24,800 $229,000
Q1 2020 May 14, 2020	BUY	$3.51 - $8.48 $35,100 - $84,800	10,000 New	10,000 $47,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.